B

Beijing Luzhu Biotechnology Co Ltd
HKEX:2480

Watchlist Manager
Beijing Luzhu Biotechnology Co Ltd
HKEX:2480
Watchlist
Price: 23.04 HKD -0.86% Market Closed
Market Cap: 4.6B HKD

Net Margin
Beijing Luzhu Biotechnology Co Ltd

0%
Current
0%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-135.9m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Beijing Luzhu Biotechnology Co Ltd
Glance View

Market Cap
4.6B HKD
Industry
Biotechnology

Beijing Luzhu Biotechnology Co., Ltd. engages in the development, production, and sale of active pharmaceutical ingredients. The company is headquartered in Beijing, Beijing. The company went IPO on 2023-05-08. The firm is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The firm operates in the domestic market and overseas markets.

Intrinsic Value
34.02 HKD
Undervaluation 32%
Intrinsic Value
Price
B
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-135.9m
/
Revenue
0
What is the Net Margin of Beijing Luzhu Biotechnology Co Ltd?

Based on Beijing Luzhu Biotechnology Co Ltd's most recent financial statements, the company has Net Margin of 0%.

Back to Top